<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Orexigen Therapeutics</title>
	<atom:link href="http://www.stockbloghub.com/tag/orexigen-therapeutics/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ARNA) Arena Pharmaceuticals is Denied FDA Approval for Obesity Candidate Drug</title>
		<link>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417</link>
		<comments>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:44:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56417</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company’s obesity candidate lorcaserin citing tumor-related safety concerns. The US regulatory authority issued a complete response letter (CRL) stating that the efficacy of the drug in non type II diabetes obese patients was found to be marginal. The FDA asked the company to submit the final study report of the BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in DiabetesMellitus) study which evaluated the efficacy of lorcaserin against placebo in obese and overweight patients suffering from type II diabetes. Arena intends to present top-line data from the study shortly and complete the study report by the end of this year. The FDA stated further that it may ask ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Removes Obesity Drug Meridia From Market</title>
		<link>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707</link>
		<comments>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707#comments</comments>
		<pubDate>Wed, 13 Oct 2010 02:14:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54707</guid>
		<description><![CDATA[Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs&#8217; decision was based on a request made by the US Food and Drug Administration (FDA). The FDA’s request was based on data from a post-marketing study (SCOUT &#8211; Sibutramine Cardiovascular OUTcome Trial), which showed that patients treated with Meridia experienced a 16% increase in the risk of cardiovascular events (non-fatal heart attack/stroke, the need to be resuscitated once the heart has stopped, and death) compared to placebo. Results also showed that the difference in weight loss between the Meridia and placebo arms was small. In mid-Sep 2010, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had conducted a meeting to review the drug. While 8 panelists were in favor of removing the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) FDA to Review Vivus Drug</title>
		<link>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446</link>
		<comments>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446#comments</comments>
		<pubDate>Thu, 15 Jul 2010 04:41:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43446</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently posted briefing documents on its website ahead of the review of Vivus’ (VVUS) obesity drug Qnexa by the FDA’s Endocrinologic &#38; Metabolic Drugs Advisory Committee. While the FDA said that all three doses of Qnexa were efficacious for weight loss, the agency has raised questions regarding certain safety issues. The FDA has highlighted five areas which will be discussed by the panel. These include psychiatric-related and cognitive-related adverse events, metabolic acidosis, cardiovascular events and the effect of the drug on pregnant women. We believe the main focus will be on increased adverse event reports of depression, anxiety, and sleep disorders and the potential clinical significance of the increase in heart rate. The advisory panel will be meeting on Jul 15 to discuss ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review</title>
		<link>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187</link>
		<comments>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32187</guid>
		<description><![CDATA[Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Obesity Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994</link>
		<comments>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994#comments</comments>
		<pubDate>Thu, 25 Feb 2010 23:18:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28994</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies. The decision is based on encouraging 52-week results on the combination treatment from a blinded, placebo-controlled phase II extension study in which the combination succeeded in achieving the key target of sustained and robust weight loss. Results showed that patients who continued treatment with pramlintide/metreleptin for 52 weeks experienced sustained weight loss, while those on placebo regained almost all of their weight. The combination treatment was found to be most effective in patients with a body mass index (BMI) less than 35 kg/m2. The combination treatment was generally well tolerated, with nausea and injection-site-adverse events being the most common side effects ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck &amp; Co Ends Deal with Arena Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734</link>
		<comments>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:11:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23734</guid>
		<description><![CDATA[Merck &#38; Co (MRK) recently informed its partner Arena Pharmaceuticals (ARNA) that it was pulling out of a collaboration agreement pertaining to the development of an atherosclerosis drug. The decision by Merck to discontinue the development of the candidate, MK-1903, a niacin receptor agonist for treating atherosclerosis, followed disappointing results from a recently completed mid-stage study. The randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability and potential efficacy in patients with dyslipidemia. The study did not meet the primary objective for efficacy. The drug failed to significantly raise patients&#8217; levels of good cholesterol (HDL) compared to a placebo. However, Merck’s decision to pull out of the deal was not related to any safety concerns pertaining to the drug. Atherosclerosis is the thickening of the artery walls which often leads to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Amylin Pharmaceuticals Strikes First on Obesity</title>
		<link>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415</link>
		<comments>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:30:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19415</guid>
		<description><![CDATA[Almost all of the news in the obesity race has been made recently by three small biotech companies &#8212; Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race. Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesity. As part of the transaction, Amylin will receive a one-time up-front payment of $75 million from Takeda. Amylin is also eligible to receive additional payments based on development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Arena Pharmaceuticals&#8217; Lorcaserin Has Safety Edge</title>
		<link>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751</link>
		<comments>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751#comments</comments>
		<pubDate>Mon, 21 Sep 2009 17:19:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15751</guid>
		<description><![CDATA[Results from Arena Pharmaceuticals’ (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

